KASTELEIN JOHANNES JACOB PIETER (Chief Scientific Officer) sold 7.5% of their position (6K shares) of NEWAMSTERDAM PHARMA CO N.V. on the open market
Open‑market sale worth $199.5K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 1/7/2026ACC: 0001193125-26-006662
DirectorOfficer· Chief Scientific Officer
Since Mar 2026
+134.50K
Net shares
Net buyer
$199.5K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
140.50K acquired · 6K disposed
Non-Derivative Transactions2
Ordinary Shares
Direct
Shares
−6K
Price / share
$33.25
Trade value
$199.50K
% of position
7.5%
1/5/2026
79.48K→73.48K
Ordinary Shares
Direct
Shares
+25.50K
Price / share
—
Trade value
—
% of position
34.7%
1/7/2026
73.48K→98.98K
Total
Net shares
+19.50K
Net value
-$199.50K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Direct | 1/5/2026 | S · Sale | −6K | $33.25 | $199.50K | 7.5% | 79.48K | 73.48K |
| Ordinary Shares Direct | 1/7/2026 | A · Award | +25.50K | — | — | 34.7% | 73.48K | 98.98K |
| Total | +19.50K | -$199.50K | ||||||
Derivative Transactions1
Option (right to buy)
Direct
Converts to
Ordinary Shares
115K shares
Shares
+115K
Strike price
35.45
Held after
115K
Exercisable
—
1/7/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Option (right to buy) Direct | Ordinary Shares115K shares | 1/7/2026 | A · Award | +115K | 35.45 | — | 115K |